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AbsTrACT
Objective To assess health- related quality of life in 
patients with non- dysplastic Barrett’s oesophagus 
(NDBO) and endoscopically treated dysplastic Barrett’s 
oesophagus (DBO).
Design This quantitative, self- administered questionnaire 
study was conducted across three National Health Service 
hospitals. Data were collected from three other cohorts; 
gastro- oesophageal reflux disease (GORD), colonic polyp 
surveillance and healthy individuals. Fisher’s exact and 
Spearman’s rank correlation tests were used for analysis. 
Propensity score matching adjusted for age, sex and 
comorbidities.
results 687 participants were eligible for analysis 
(NDBO n=306, DBO n=49, GORD n=132, colonic polyps 
n=152 and healthy n=48). 53% of NDBO participants 
reported similarly high cancer worry, comparable to DBO 
(50%, p=0.933) and colonic polyp participants (51%, 
p=0.355). Less cancer worry was reported in GORD 
participants (43.4%, p=0.01 vs NDBO). NDBO participants 
reported anxiety in 15.8% and depression in 8.6% of 
cases, which was similar to the other disease cohorts. 
Moderate or severe heartburn or acid regurgitation was 
found in 11% and 10%, respectively, in the NDBO cohort, 
comparable to DBO participants (heartburn 2% p=0.172, 
acid regurgitation 4% p=0.31) but lower (better) than 
GORD participants (heartburn 31% p=<0.001, acid 
regurgitation 25% p=0.001). NDBO participants with 
moderate or severe GORD symptoms were associated 
with higher rates of anxiety (p=<0.001), depression 
(p=<0.001) and cancer worry (p=<0.001). NDBO patients 
appropriately perceiving their cancer risk as low had lower 
rates of cancer worry (p=<0.001).
Conclusion This study provides insight into the problems 
Barrett’s oesophagus patients may face. Future care 
pathways must be more patient focussed to address 
misconceptions of cancer risk, oesophageal cancer related 
worry and GORD symptom control.
IntroductIon
The incidence of oesophageal adenocarcinoma 
(OAC) and its precursors, gastro- oesophageal 
reflux disease (GORD) and Barrett’s oesoph-
agus (BO), are increasing.1 2 BO is a well- 
established, relatively low risk,3 precancerous 
summary box
What is already known about this subject?
 ► Health- related quality of life (HRQoL) assessment 
provides a valuable insight into disease impact at an 
individual and population level.
 ► HRQoL is a well- recognised outcome measure for 
healthcare delivery and treatment efficacy.
 ► The annual cancer conversion rate from non- 
dysplastic Barrett’s oesophagus (BO) to oesopha-
geal adenocarcinoma is relatively low.
 ► Few historical studies concerning HRQoL in BO are 
outdated and cannot be translated to current care 
pathways.
What are the new findings?
 ► This study provides a valuable insight into the prob-
lems patients with BO may face and efficacy of cur-
rent National Health Service BO care pathways.
 ► Oesophageal cancer related worry in patients with 
non- dysplastic BO appears disproportional to their 
risk.
 ► Oesophageal cancer related worry is comparable 
between non- dysplastic BO and treated dysplastic 
BO cohorts despite significant differences in actual 
risk.
 ► Gastro- oesophageal reflux disease (GORD) symp-
tom control is an important component of HRQoL 
with >10% non- dysplastic Barrett’s oesophagus 
patients reporting moderate- to- severe symptoms.
 ► Poor symptom control and misconceptions of oe-
sophageal cancer risk are associated with greater 
cancer specific worry.
How might it impact on clinical practice in the 
foreseeable future?
 ► Future care pathways should be more patient fo-
cussed with greater reassurance and communi-
cation to address; misconceptions of cancer risk, 
GORD symptom control, oesophageal cancer spe-
cific worry.
 ► This research highlights the key areas of interest for 
the development and validation of a dedicated BO 
Patient Reported Outcome Measure (PROM).
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diagnosis that requires long- term endoscopic surveillance 
as per multinational guidelines.4 5 Without early detec-
tion, OAC is often devastating in terms of prognosis.6 
Considering the relatively low annual cancer conversion 
rate of BO to OAC, 0.33% in most recent meta- analysis,3 
the majority of patients with BO will never develop OAC 
but must live with the burden of a precancerous label. 
Recent advances in endoscopic therapy (ET) for those who 
develop dysplasia or early OAC are increasingly effective 
with durable outcomes.7 However, these patients still face 
multiple endoscopic procedures, long- term surveillance 
and risk of disease recurrence.4 5 8 9 Little is known about 
how these diagnoses and care pathways affect patients 
health- related quality of life (HRQoL).
HRQoL ‘reflects physical, social and emotional atti-
tudes and behaviours of an individual as they relate to 
their prior and current health state’.10 HRQoL is therefore 
a key outcome measure of healthcare delivery and treat-
ment efficacy. Despite this, HRQoL assessment in many 
studies is poorly done or tokenistic.11 To date, there is no 
validated BO specific patient reported outcome measure. 
Past quantitative research has therefore used numerous 
instruments to capture the impacts of this precancerous 
disease. Significant reductions in generic (eg, SF-36 form) 
and disease specific (GORD or gastrointestinal) HRQoL 
scores have been reported. A prior literature review12 and 
qualitative research13 has identified key areas of interest 
when measuring HRQoL in BO patients. These include 
GORD symptom control, psychological effects (eg, anxiety 
and depression), worry of oesophageal cancer and burden 
of repeated surveillance endoscopies. The few historical 
studies concerning BO HRQoL are outdated and cannot 
be translated to current care pathways. Other limitations 
include underpowered samples, use of a single measure-
ment tool or a lack of appreciation for confounding factors. 
Even less research has been conducted regarding the impact 
of dysplastic Barrett’s oesophagus (DBO).14–16 Therefore, 
the true prevalence of HRQoL detriments remains largely 
unknown. Quantitative assessment of HRQoL will provide 
a valuable insight into the problem’s patients may face, effi-
cacy of current care and highlight areas future healthcare 
delivery can focus resources on. This study aimed to assess 
HRQoL in patients with non- dysplastic BO and endoscopi-
cally treated DBO compared with other common gastroin-
testinal disorders and healthy individuals.
Methods
This quantitative, multicentre, self- administered question-
naire study recruited from three National Health Service 
(NHS) hospitals within the North West of England two 
of which provide ET for DBO. Simultaneously, data were 
collected from three other cohorts including a prior 
diagnosis of GORD without BO, colonic polyps requiring 
surveillance and healthy individuals without comorbid 
disease. All participants were >18 years old with no upper 
age limit. Participants were recruited via postal invite or 
in person. In order to minimise any acute impact on their 
responses, postal invitations occurred at a time indepen-
dent of endoscopy or outpatient appointment. Likewise, 
those recruited in person were instructed to complete 
the survey at home at a time independent (>4 weeks) of 
a hospital appointment. For further information relating 
to the participant groups and recruitment please see the 
online supplementary file.
hrQoL instruments; scoring and data management
Based on previous qualitative research and literature review, 
the following self- administered instruments were included 
in the questionnaire.12 13 For further information on each 
HRQoL instrument, scoring and data management please 
see the online supplementary file.
The Short Form 36 (36 items, 8 domains)
The SF-36 measures generic HRQoL allowing comparison 
between different diseases and the general population.17 It 
is the most extensively used and validated generic measure 
across many populations.
The Cancer Worry Scale (6 Domains, 4-point Likert scale)
The Cancer Worry Scale (CWS) is designed to measure 
cancer specific worry and impact of worry on daily func-
tioning.18 It has been successfully used in assessing fear of 
developing cancer or cancer recurrence in breast, ovarian 
and bowel cancer settings.19–21 The following score cut- offs, 
defined by Custers and colleagues, were adopted; <10 as 
negative, 10 to 11 as borderline and ≥12 as positive.22 This 
score was accompanied by an assessment of numerical and 
perceived risk of developing cancer using a 7- point Likert 
scale.
Hospital Anxiety and Depression Score (2 domains, 14 items, 
4-point Likert scale)
The Hospital Anxiety and Depression Score (HADS) is 
the most extensively used and validated screening tool 
for anxiety and depression.23–25 The author proposed cut- 
off points for these scores were adopted; 0 to 7 suggests 
the absence of symptoms, 8 to 10 indicates the presence 
of symptoms to a moderate degree with doubtful cases, 
≥11 indicates significant symptoms which correspond to 
confirmed cases.23 26
The Gastrointestinal Symptom Rating Scale (15 items, 5 domains, 
4-point Likert scale)
This extensively used symptom specific score measures 
frequency, intensity, duration and impact on daily life. It 
can identify clinically important change and discriminates 
well between each domain, most markedly in reflux and 
indigestion.27 28 There is no defined score cut- offs.
statistical analysis
HRQoL outcomes are multidimensional with no single 
identifiable endpoint. Therefore, our primary outcomes 
were each of the questionnaire subcategories. Fisher’s 
exact test was used to identify associations between diag-
nostic groups and questionnaire items.
Further analysis examined for differences in the 
questionnaire subdomains between the non- dysplastic 
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Table 1 Participant demographics
NBDO n=306 DBO n=49 GORD n=132 Colonic polyp n=152 Healthy n=48
Age (years) Mean 64.6 71 60.9 68.6 50.3
  Range 26–85 55–84 30–90 48–89 20–80
Sex Male 198 44 72 100 24
  Female 108 5 60 52 23
  % male 64.70% 89.80% 60.90% 65.80% 51.10%
Employment status Employed 32.70% 8.20% 35.90% 17.30% 85.10%
  Unemployed 6.70% 0.00% 10.90% 2.70% 4.30%
  Retired 60.60% 91.80% 53.10% 80.00% 10.60%
Family history Cancer 20.60% 24.50% 27.80% 16.90% 50.00%
  Disease specific cancer 7.2% (OAC) 2% (OAC) 5.4% (OAC) 22.5% (CRC) NA
  Chronic disease 15.40% 16.30% 21.50% 13.90% 33.30%
Carer Yes 6.90% 14% 13.20% 11.30% 2.10%
Smoking Never 43.30% 26.50% 49.60% 39.70% 70.80%
  Current 11.10% 4.10% 11.60% 10.60% 8.30%
  Ex- smoker 45.60% 69.40% 38.80% 49.70% 20.80%
PPI usage Yes 95.10% 100.00% 84.60% 45.70% 0.00%
Antidepressant usage Yes 8.50% 10.20% 18.30% 10.60% 0.00%
Prague M classification Mean 3.6 3.9 NA NA NA
Comorbidity prevalence None 29.40% 14.30% 25.00% 21.70% 100.00%
  1–2 54.20% 59.20% 55.30% 57.90% 0%
  3–4 16.00% 22.40% 17.40% 17.10% 0%
  >4 0.30% 4.10% 2.30% 3.30% 0%
CRC, colorectal cancer; DBO, dysplastic Barrett’s oesophagus; GORD, gastro- oesophageal reflux disease; NDBO, non- dysplastic Barrett’s 
oesophagus; OAC, oesophageal adenocarcinoma; PPI, proton pump inhibitor.
Barrett’s oesophagus (NDBO) group and the other 
groups separately using the average treatment effects, 
after propensity scores were calculated to adjust for 
potential confounders. Within this analysis, individuals 
were matched over the estimated probability of being at 
the diagnostic group, called propensity score, adjusted 
for sex, age and number of comorbidities. The healthy 
cohort, who lack comorbidities, were adjusted for age 
and sex only.29 Thus, individuals with the same propen-
sity score have similar baseline observed characteristics, 
that is, age, sex and comorbidities. A sensitivity analysis 
to ensure the results of propensity matching score were 
consistent was implemented using nearest neighbour 
matching, where the closest individuals were matched 
according to a predefined distance.30
Finally, Fisher’s exact and Spearman’s rank correlation 
tests were performed to examine for possible associations 
between variables, that is, test for association between 
reflux symptoms and worry of oesophageal cancer or 
HADS anxiety.
A p value of <0.05 was considered clinically significant. 
When interpreting SF-36 scores; mean scores for each 
domain were converted into norm- based scores, as per 
author guidance,31 with a p value <0.05 accompanied 
with a coefficient of +/−3 points considered clinically 
significant.31 For further information on SF-36 norm- 
based scoring please see the online supplementary 
file. All statistical analyses were performed using Stata 
V.15.32
resuLts
response rates and demographics
Two thousand and seventy- five individuals were invited 
to participate across all groups with an overall response 
rate of 38.4% (see online supplementary figure 2.1-1). 
The relatively low response rate likely reflects the 
use of postal invitation and the length of the survey. 
Responder versus non- responder characteristics for 
the BO group can be seen in the online supplemen-
tary table 2.1-1. These data suggests the non- responder 
group have fewer comorbidities, however this may be 
due to differences in recording than a true difference 
between the groups. Comorbidities for the responders 
were self- reported and obtained via clinical coding 
databases whereas the non- responders were identified 
from coding alone. Participant demographics for all 
four groups is displayed in table 1 (further breakdown 
of comorbidity prevalence and subcategories can be 
found in the online supplementary table 2.1-2).
Generic health-related quality of life (sF-36)
The mean norm- based scores, calculated against an age 
and sex matched UK population norm, are depicted in 
figure 1. The healthy cohort consistently scored at or 
copyright.
 o
n
 M
ay 10, 2020 at BVA. Protected by
http://bmjopengastro.bmj.com/
BM
J O
pen G
astroenterol: first published as 10.1136/bmjgast-2019-000357 on 31 March 2020. Downloaded from 
4 Britton J, et al. BMJ Open Gastro 2020;7:e000357. doi:10.1136/bmjgast-2019-000357
Open access 
Figure 1 SF-36 norm based scores. Norm based scores give a direct comparison to a general population norm without 
having to cross reference to norm values. The scores for all groups have been age and sex matched to a prior UK general 
population norm. A score of 50 with a deviation of +/−3 points is considered comparable to the general population. Lower 
scores (<47) indicate worse HRQoL whereas higher scores (>53) indicate better HRQoL than the general population. BP, 
bodily pain; DBO, dysplastic Barrett’s oesophagus; GH, general health; GORD, gastro- oesophagealreflux disease; HRQoL, 
health- related quality of life; MCS,Mental Component Summary Score; MH, mental health; NDBO, non- dysplastic Barrett’s 
oesophagus; PCS, Physical Component Summary Score; PF, physical functioning; RE, role limitations emotional; RP, role 
limitations physical; SF, social functioning; VT, energy and vitality.
above the UK general population norm in all domains. 
All disease groups showed detriments across the phys-
ical domains, in particular bodily pain, resulting in phys-
ical component summary scores below the population 
norm (BO=46.9, DBO=45.0, GORD=45.0 and colonic 
polyps=46.3). The GORD group were also below the 
general population average for all four mental health 
domains culminating in the only disease group to record 
an Mental Component Summary (MCS) score below 
average (GORD MCS=45.3) (figure 1).
Although these data give an insight into generic 
HRQoL measures in relation to a previously published 
UK norm, it does not deliver any information to how the 
BO group compares in relation to the other cohorts and it 
remains unclear whether the generic HRQoL detriments 
seen here are due to the disease in question or other 
confounding factors such as comorbidities. In order to 
provide some insight into this, propensity score anal-
ysis was conducted where individuals of each diagnostic 
group were matched in regards to confounding factors 
and all groups were compared with the non- dysplastic 
BO cohort to look for significant differences in each 
domain. The non- dysplastic BO cohort had significantly 
lower (worse) scores across all domains compared with 
the healthy cohort. The BO cohort also had significantly 
higher (better) scores in the general health domain than 
the DBO cohort (coefficient=4.3, 95% CI=0.9 to 7.6, 
p=0.014). Otherwise the domain and summary scores 
were statistically comparable to all three disease groups. 
This suggests that initial observed differences in the mean 
scores between the groups may be related to confounders 
than the disease in question. For example, the BO cohort 
had mean scores >3 in both the energy and vitality and 
social functioning domains when compared with the 
GORD group. However, after propensity score matching 
analysis the coefficients were only +1.2 and +0.7, respec-
tively, (online supplementary table 2.1-3 shows the 
coefficient, 95% CI and p values after propensity score 
matching for age, sex and comorbidities).
Gastrointestinal symptoms
The majority of the non- dysplastic BO cohort reported 
good reflux symptom control with 11% reporting 
moderate or severe heartburn and 10% reporting 
moderate or severe acid regurgitation. These rates were 
not statistically different to the treated DBO cohort. When 
compared with GORD patients, non- dysplastic BO partic-
ipants had significantly better reflux control with 31.3% 
(p=<0.001) and 25.2% (p=0.001) of GORD participants 
reporting moderate- to- severe heartburn or acid regurgi-
tation respectively (table 2). These findings were repro-
duced when comparing the two groups reflux domain 
score (combined heartburn and acid regurgitation 
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Table 2 Gastrointestinal Symptom Rating Scale. Moderate or severe symptoms (15 items)
NDBO
n=305
DBO
n=48
GORD
n=131
Colonic polyp
n=150
Healthy
n=47
(1) Abdominal pains 13.2% (39) 9.1% (4) 19.5% (24) 10.1% (14) 0.0% (0)
p=0.208 p=0.126 p=0.073 p=<0.001*
(2) Heartburn 11.2% (33) 2.2% (1) 31.3% (40) 6.3% (9) 2.1% (1)
p=0.172 p=<0.001* p=0.011* p=0.063
(3) Acid regurgitation 10.0% (30) 4.3% (2) 25.2% (32) 2.8% (4) 0.0% (0)
p=0.31 p=0.001* p=<0.001* p=<0.001*
(4) Hunger pains 9.5% (28) 6.7% (3) 15.1% (19) 2.8% (4) 0.0% (0)
p=0.349 p=0.311 p=0.013* p=0.019*
(5) Nausea 3.7% (11) 2.2% (1) 7.1% (9) 0.0% (0) 0.0% (0)
p=0.125 p=<0.001* p=0.009* p=0.008*
(6) Rumbling 10.4% (31) 4.7% (2) 11.7% (15) 8.3% (12) 2.1% (1)
p=0.031* p=0.148 p=0.187 p=0.056
(7) Abdominal bloating 16.6% (49) 6.7% (3) 18.0% (23) 9.0% (13) 0.0% (0)
p=0.053 p=0.553 p=0.097 p=<0.001*
(8) Belching 11.1% (33) 6.5% (3) 25.6% (33) 2.1% (3) 0.0% (0)
p=0.63 p=<0.001* p=<0.001* p=<0.001*
(9) Increased flatus 14.0% (42) 15.2% (7) 27.5% (36) 8.9% (13) 0.0% (0)
p=0.581 p=0.002* p=0.417 p=<0.001*
(10) Decreased stools 25.5% (73) 19.1% (9) 31.5% (40) 21.6% (30) 15.2% (7)
p=0.433 p=0.014* p=0.771 p=0.207
(11) Increased stools 5.9% (17) 8.5% (4) 5.5% (7) 4.3% (6) 4.3% (2)
p=0.193 p=0.323 p=0.85 p=0.261
(12) Loose stools 6.8% (20) 4.4% (2) 9.8% (12) 6.3% (9) 2.1% (1)
p=0.357 p=0.044* p=0.391 p=<0.001*
(13) Hard stools 9.5% (28) 8.9% (4) 17.1% (21) 9.1% (13) 0.0% (0)
p=0.715 p=0.004* p=0.737 p=0.009*
(14) Urgency 8.5% (25) 11.1% (5) 8.9% (11) 7.0% (10) 0.0% (0)
p=0.572 p=0.207 p=0.752 p=<0.001*
(15) Incomplete evacuation 10.9% (32) 4.4% (2) 16.3% (20) 7.7% (11) 2.1% (1)
p=0.157 p=0.049* p=0.539 p=0.007*
This table compares all groups to the non- dysplastic BO cohort for each item of the GSRS. p values are derived by Fisher’s exact test.
*p values <0.05 were deemed statistically significant.
BO, Barrett’s oesophagus; DBO, dysplastic Barrett’s oesophagus; GORD, gastro- oesophageal reflux disease; GSRS, Gastrointestinal 
Symptom Rating Scale; NDBO, non- dysplastic Barrett’s oesophagus.
items) with propensity score matching analysis (see 
online supplementary table 2.1-4). It was noteworthy 
that GORD participants also exhibited other significant 
gastrointestinal symptoms when compared with non- 
dysplastic BO participants, that is, increased nausea 
(p=<0.001), belching (p=p=<0.001), flatus (p=0.002) and 
harder stools (p=0.004). This finding is supported by a 
significantly greater gastrointestinal symptom total mean 
score after propensity score matching analysis (p=0.012) 
(see online supplementary table 2.1-4). As expected, 
the healthy cohort had significantly fewer gastrointes-
tinal symptoms across all five domains and lower overall 
scores. Also, the colonic polyp patient group displayed 
significantly fewer upper gastrointestinal symptoms 
(abdominal pain p=0.006, reflux p=0.001 and indiges-
tion p=0.047 domains) but were comparable in terms of 
lower gastrointestinal symptoms with the patients with 
non- dysplastic BO.
cancer worry
A substantial proportion of non- dysplastic BO partici-
pants reported significant worry regarding oesophageal 
cancer with 53% recording positive and 17% borderline 
CWS. This finding was not significantly different to those 
treated for DBO (p=0.933) and participants undergoing 
colonic polyp surveillance (p=0.355) when questioned 
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Table 3 Cancer Worry Scale (total mean and categorical)
Total mean 
(SD)
Propensity score 
matched (average 
treatment effects) 
coefficient
(95% CI) P value
Category % 
(n)
normal (<10)
Category % 
(n)
borderline 
(10-11)
Category % 
(n)
positive (≥12)
NDBO 
versus
P value
NDBO 12.35 (4.51) 30.5% (91) 16.8% (50) 52.7% (157)
DBO 12.67 (4.95) −2.525 (−4.582 to −0.468) 0.016* 33.3% (16) 16.7% (8 50.0% (24) p=0.933
GORD 10.88 (4.98) 2.302 (0.984 to 3.621) 0.001* 45.7% (59) 10.9% (14) 43.4% (56) p=0.01*
Colonic 
polyp
11.58 (3.93) 0.717 (−0.441 to 1.875) 0.225 36.2% (54) 12.8% (19) 51.0% (76) p=0.355
Healthy 10.02 (3.31) 3.448 (1.969 to 4.927) <0.001* 47.9% (23) 22.9% (11) 29.2% (14) p=0.007*
This table compares all groups to the non- dysplastic cohort using both mean scores, after propensity score matching, and the categorical 
breakdown (normal, borderline and positive). P values are derived by Fisher’s exact test.
*p values <0.05 were deemed statistically significant.
DBO, dysplastic Barrett’s oesophagus; GORD, gastro- oesophageal reflux disease; NDBO, non- dysplastic Barrett’s oesophagus.
regarding colorectal cancer. GORD participants reported 
significantly less oesophageal cancer worry compared 
with non- dysplastic BO participants (p=0.01), however 
43% still reported a positive CWS (table 3). This finding 
is despite 83% (n=109/132) of GORD participants having 
undergone a prior reassuring and relatively recent (mean 
0.9 years.) gastroscopy. Healthy participants also reported 
high rates of worry (29%) when asked about cancer in 
general.
cancer risk perception
The annual incidence of disease progression with BO 
is between 0.2% to 0.4% compared with that of disease 
recurrence in ET treated DBO of 1% to 2%.3 9 33 34 Based 
on this, the majority of the BO cohort either underes-
timated (43%) or overestimated (34%) their numerical 
1- year risk, leaving only 22% who correctly chose either 
0.2% to 0.4%. DBO participants tended to under (75%) 
rather than over (8%) estimate their numerical risk of 
disease recurrence with only 18% choosing appropriately 
(see online supplementary table 2.1-5).
However, an accurate understanding of numerical risk 
may not be important for patients or indeed correlate 
with their perception of risk. The corresponding items 
on the perceived risk scale show a greater percentage 
of BO and DBO patients who perceive their risk more 
accurately (32% in both groups). If ‘very small’ is also 
included in this calculation for non- dysplastic BO 
patients then this increases to 59% (n=169) of patients 
who selected the lower end of the scale and fundamen-
tally perceive their risk as ‘small’. The result produced by 
the same calculation for the DBO group is comparable 
(n=27, 61%), suggesting they have a similar risk percep-
tion of OAC as patients who have never had dysplasia. 
Numerical and perceived risk scales correlated with each 
other across three of the five diagnostic groups (BO, 
DBO and colonic polyps).
The incidence of OAC in GORD is well established,35 36 
although substantially lower than in BO cohorts. This 
study found many GORD patients worry about OAC 
(43.4%) with 10.6% perceiving their risk as large. Like-
wise, the incidence of colorectal cancer (CRC) in patients 
engaging in polyp surveillance in the UK is low (208/100 
000 per year) and significantly reduced by surveillance. 
The risk in patients undergoing surveillance who lack 
high- risk features (eg, poor- quality colonoscopy, prox-
imal polyps, high- grade dysplasia or adenoma >20 mm) 
may be comparable or lower to that of the general 
population.37 The majority of patients within this study’s 
cohort were either intermediate (57%) or low (26%) risk 
as per current national guideline definitions.38 Despite 
the known protective effects of adenoma surveillance, 
13.8% of participants in this study perceived their risk as 
large with 51% reporting a positive Cancer Worry Score 
in relation to CRC.
Psychological impact
The prevalence of anxiety within the non- dysplastic 
BO cohort was 15.8% with a further 15.2% recording a 
borderline result. Rates of depression were lower (8.6% 
positive and 10.6% borderline) (table 4). Antidepressant 
usage was highest in the GORD group (18%) which is 
also reflected by the occurrence of mental health disor-
ders which was highest in this cohort (33%) (see online 
supplementary table 2.1-2). One may therefore expect 
significantly higher rates of anxiety and depression in this 
group. However, all the disease groups were statistically 
comparable to the non- dysplastic BO cohort. Only the 
healthy group demonstrated significantly different scores 
with less anxiety (HADS A positive=4.2%, p=0.001) and 
depression (HADS D positive=0%, p=0.006). This finding 
was reproduced when the HADS mean scores (HADS A 
mean and HADS D mean) were compared after propen-
sity score matching analysis (p=<0.001).
correlation of measures
BO patients who reported moderate or severe GORD 
symptoms (heartburn, reflux) were associated with 
higher rates of both anxiety (p=<0.001, p=<0.001) 
and depression (p=<0.001, p=<0.001). Higher (worse) 
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Table 4 Hospital anxiety and depression scores
Group
HADS A 
total
mean (SD)
Propensity score matched 
(average treatment 
effects) coefficient
(95% CI)
HADS A 
mean
NDBO 
versus 
other
P value
HADS A 
normal % (n)
HADS A 
borderline 
% (n)
HADS A 
positive % (n)
HADS A 
category
NDBO 
versus 
other
P value
NDBO 5.5 (4.5) 69.0% (209) 15.2% (46) 15.8% (48)
DBO 4.7 (3.6) −0.48 (−2.245 to 1.285) 0.594 83.7% (41) 8.2% (4) 8.2% (4) 0.125
GORD 6.6 (5.0) −0.433 (−1.53 to 0.665) 0.44 64.1% (84) 13.7% (18) 22.1% (29) 0.301
Colonic 
polyp
4.7 (3.9) 0.805 (−0.123 to 1.733) 0.089 75.7% (112) 12.8% (19) 11.5% (17) 0.329
Healthy 2.8 (2.9) 4.317 (3.589 to 5.045) <0.001* 93.8% (45) 2.1% (1) 4.2% (2) 0.001*
DBO, dysplastic Barrett’s oesophagus; GORD, gastro- oesophageal reflux disease; HADS, Hospital Anxiety and Depression Score; NDBO, 
non- dysplastic Barrett’s oesophagus.
  
HADS D 
total
mean (SD)
Propensity score matched 
(average treatment 
effects) coefficient
(95% CI)
HADS D 
mean
NDBO 
versus 
other
P value
HADS D 
normal % (n)
HADS D 
borderline 
% (n)
HADS D 
positive % (n)
HADS D 
category
NDBO 
versus 
other
P value
NDBO 4.2 (4.0) 80.9% (245) 10.6% (32) 8.6% (26)
DBO 3.7 (3.1) −0.015 (−1.227 to 1.197) 0.981 79.6% (39) 18.4% (9) 2.0% (1) 0.094
GORD 5.5 (4.4) −0.59 (−1.788 to 0.607) 0.334 71.0% (93) 14.5% (19) 14.5% (19) 0.065
Colonic 
polyp
4.0 (3.6) 0.488 (−0.414 to 1.391) 0.289 83.8% (124) 8.1% (12) 8.1% (12) 0.734
Healthy 1.8 (2.2) 3.117 (2.173 to 4.062) <0.001* 97.9% (47) 2.1% (1) 0.0% (0) 0.006*
This table compares all groups to the non- dysplastic cohort using both mean scores, after propensity score matching, and the categorical 
breakdown (normal, borderline and positive). P values are derived by Fisher’s exact test.
*p values <0.05 were deemed statistically significant.
DBO, dysplastic Barrett’s oesophagus; GORD, gastro- oesophageal reflux disease; HADS, Hospital Anxiety and Depression Score; NDBO, 
non- dysplastic Barrett’s oesophagus.
scores in the reflux domain (combined items) were also 
associated with higher (worse) Cancer Worry Scores 
(p=<0.001). Patients with higher cancer worry were asso-
ciated with significant anxiety (p=<0.001) and depres-
sion (p=<0.001). Those who correctly perceived their 
cancer risk as low tended to have significantly lower rates 
of cancer worry (p=<0.001). This was also the case for 
numerical risk estimation (p=0.003).
dIscussIon
The major finding in this study was the high prevalence 
of OAC- related cancer worry among patients with non- 
dysplastic BO undergoing surveillance. It also appears 
that after ET for dysplasia or early OAC patient cancer 
specific worry is comparable to that of patients who have 
never had dysplasia. This finding is supported by the 
HRQoL data from the Ablation of Intestinal Metaplasia 
containing dysplasia (AIM) dysplasia trial.14 At 12 months 
follow- up, patients who had undergone successful radiof-
requency ablation (RFA) for DBO reported significantly 
less worry than those who had received a sham procedure. 
Interestingly this was at a time when the true efficacy of 
ET was unknown. It therefore appears that informing 
patients they no longer have dysplasia or indeed BO is 
very reassuring to them. These findings need further 
delineation with a prospective paired pre and post treat-
ment HRQoL study. The other study concerning cancer 
worry and DBO treatment was conducted by Rosmolen 
and colleagues.15 They compared oesophageal cancer 
worry of endoscopically treated high- grade dysplasia or 
early OAC to patients treated surgically in a single centre 
Netherlands study. Significantly higher levels of cancer 
worry were found in ET patients compared with surgically 
managed ones with similar disease stage. This may reflect 
the perceived risk of recurrence associated with having 
an intact oesophagus, especially when one considers the 
asymptomatic nature of disease progression. The payoff 
for lower levels of worry, in this surgical cohort, was 
significantly worse oesophageal and cancer related symp-
toms. This finding is supported by previous HRQoL data 
concerning oesophagectomy- treated patients.39 It must 
be noted however that this study was single centre, rela-
tively underpowered and did not control for comorbidi-
ties. Interestingly, the authors also chose not to measure 
cancer worry, anxiety or depression in the non- dysplastic 
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BO cohort as they did not expect these to be prevalent. 
Our study not only found prevalent oesophageal cancer 
worry in the non- dysplastic BO cohort but also high levels 
in GORD patients. This is despite a substantially lower rela-
tive risk and recent reassuring endoscopy in the majority 
of cases. Prior research estimates the incidence of OAC 
in males aged 65 years with daily reflux is 74.7/100 000 
per annum. This risk drops off significantly below the age 
of 55 and is even lower in females. In fact, the risk of OAC 
in females with GORD is lower than that of males without 
GORD.35 Surprisingly the healthy cohort reported non- 
specific cancer worry in 29% or participants. This may 
reflect the finding that 50% of this cohort reported a 
family history of cancer and also the use of NHS staff as 
healthy volunteers. In previous studies healthcare staff 
have exhibited higher anxiety and depression rates when 
compared with the general population.40 41
The anxiety and depression scores found in this 
study are comparable to that reported by Cooper and 
colleagues in a previous UK BO cohort with mean HADS 
A scores of 5.5 (current study) and 6.1 (Cooper et al) 
and mean HADS D scores of 4.2 (current study) and 4.0 
(Cooper et al).42 The incidence of combined abnormal 
and borderline cases were 31% versus 39% for anxiety 
and 19% versus 14% for depression, respectively.42 
Subanalysis of the non- dysplastic BO cohort in this study, 
suggests that GORD symptom severity is associated with 
oesophageal cancer worry, anxiety and depression. The 
causality or direction of these associations cannot be 
concluded from this analysis alone. Yet, when interpreted 
alongside qualitative research, conducted by this research 
group, a greater understanding of these interactions can 
be achieved. This showed that, in some cases, GORD 
symptom flares lead to worry or anxiety regarding disease 
progression. Other factors also instigated in cancer worry 
included having dependents, an anxious predisposition 
and inadequate disease specific knowledge, particularly 
cancer risk perception.13 Indeed, perception of oesopha-
geal cancer risk in this quantitative study correlated well 
with severity of cancer worry, as did numerical risk.
The data captured in this study suggest symptom 
control for the majority of BO patients is reasonable 
with approximately 10% reporting moderate- to- severe 
symptoms. Symptom severity is comparable to the DBO 
cohort, a finding consistent with that of Rosmolen and 
colleagues.15 GORD patients appear to have signifi-
cantly worse symptoms, a finding supported by prior 
studies.43–45 There are a number of potential reasons for 
this. First, higher rates of PPI usage in non- dysplastic BO 
cohorts (95.1% vs 84.6% in this study). Second, a signif-
icant minority of BO patients are diagnosed inciden-
tally and have never suffered GORD symptoms. Finally, 
GORD cohorts may also contain more participants with 
functional gastrointestinal disorders. This may be the 
case in this study as the GORD cohort reported signifi-
cantly worse gastrointestinal symptoms outside the reflux 
domain. Also, of those who had undergone a recent 
endoscopy (109/132), 46% (n=50) had non- erosive 
disease, 32% (n=35) had reflux oesophagitis and 22% 
(n=24) had dyspepsia with or without gastritis. It is worth 
noting that quantitative measurement of symptoms 
may miss important flare- ups depending on the recall 
period of the questionnaire used. Prior qualitative work 
has suggested these flares, although infrequent, can be 
disruptive for patients, difficult to manage and impact 
significantly on HRQoL.13
Generic HRQoL measures (SF-36), in this study, 
suggest BO patients have significantly lower (worse) phys-
ical component scores, in particular bodily pain when 
compared with an age and sex matched UK population 
norm. These findings are consistent with Lippmann and 
colleagues45 who examined HRQoL in BO and GORD 
patients in a single tertiary centre in the USA. Consid-
ering BO reflux symptom control is generally good, this 
finding is unlikely to be solely related to BO and may 
reflect comorbid disease. Otherwise, using this metric 
alone (SF-36), BO patients could be considered to have 
a HRQoL close to that of the general population. This 
study also highlights the importance of controlling for 
potential confounding factors when measuring HRQoL, 
especially when making comparisons between disease 
groups. Without adjusting for these, data can easily be 
misinterpreted.
This study highlights key areas of disease impact on BO 
patients. These findings are important to consider when 
implementing BO care pathways. Considering histor-
ical BO care has been reported as inconsistent, inade-
quate or non- existent4 13 46 there needs to be a greater 
focus on counselling patients regarding cancer risk with 
perhaps an emphasis on using words rather than numer-
ical values in explanations. Previous research has shown 
that patients’ perception of risk, rather than knowledge 
of numerical risk, is what drives health behaviour and 
influences HRQoL.47 48 Although the majority of patients 
with non- dysplastic BO in this study, and prior research,49 
perceive their cancer risk as low there is still a significant 
minority who overestimate it. Lowering perceived cancer 
risk in these patients may in turn reduce cancer specific 
worry, anxiety and depression. This appears key to non- 
dysplastic BO participants who appear more likely to 
overestimate their cancer risk (34% overestimate numer-
ical risk and 42% overestimate perceived risk) compared 
with treated dysplastic/OAC patients (8% overestimate 
numerical risk and 7% overestimate perceived risk). 
A prior US cohort study of non- dysplastic BO patients, 
conducted by Shaheen and colleagues, found even higher 
rates (68%) of numerical risk overestimation.50 Discus-
sions concerning cancer risk are also important when 
not pursuing surveillance, for example newly diagnosed 
patients who do not meet current surveillance criteria. 
Reassurance for BO patients may also be provided by a 
negative surveillance endoscopy. DBO treated patients 
remain under greater endoscopic scrutiny, which may be 
one explanation as to why they have a perceived cancer 
risk similar to that of non- dysplastic levels. The reassuring 
findings of endoscopy should be communicated by the 
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endoscopist immediately and effectively to all, including 
GORD and colonic polyp patients undergoing endoscopy 
who typically do not receive further clinical follow- up. 
This interaction between endoscopist and patient must 
not be underestimated. Cooper and colleagues found 
lower (worse) trust in physician scores were associated 
with greater levels of anxiety and depression.42 Similarly 
physician- patient communication surrounding surveil-
lance endoscopies has been shown to be vitally important 
to patients in prior qualitative work.13 51 Surveillance 
intervals for some patients can be long (3 to 5 years) 
and the reassurance of a negative endoscopy will natu-
rally dwindle over time. It may therefore be appropriate 
to provide BO patients with a direct access to secondary 
care services in- between their endoscopies.
Limitations
This study is not without limitations. First, the response 
rate is relatively low. This may lead to significant differ-
ences between responder and non- responder character-
istics introducing bias, which may reduce reliability and 
generalisability of the results. To provide some insight 
into this, responder and non- responder non- dysplastic 
BO characteristics have been provided (see online 
supplementary table 2.1-1). Second, the demographics of 
each cohort are not perfectly matched. However, this has 
been accounted for within the analysis through propen-
sity score matching which included age, sex and comor-
bidities. Finally, socioeconomic status was not recorded 
which is another potential confounding factor in HRQoL 
research. Despite these limitations the data captured are 
of good quality, multicentre and consider a range of 
potential disease impacts.
concLusIons
To our knowledge this study provides the largest and most 
comprehensive quantitative HRQoL measurement of BO 
patients within the UK’s NHS. Based on these findings, 
patients require greater reassurance and communication 
concerning oesophageal cancer risk. Current and future 
care pathways must be more patient focussed with greater 
attention given to assessing and addressing misconcep-
tions of cancer risk, oesophageal cancer related worry 
and GORD symptom control.
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